Research on the menopause in the 1990s

World Health Organization - Technical Report Series

Volumn , Issue 866, 1996, Pages 1-107

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; VITAMIN D;

BREAST CANCER; CULTURAL FACTOR; DEMOGRAPHY; ENDOCRINOLOGY; FEMALE; HEALTH PROMOTION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOPOROSIS; REVIEW; SYMPTOM;

EID: 0029806162     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (497)

1. World Bank. World development report 1993: investing in health. New York, NY, Oxford University Press, 1993.
2. Meirik O, Benagiano G. Hormone replacement therapy: its impact on the risk of breast cancer. In: Popkin DR, Peddle LJ, eds. Women's health today. The Proceedings of the XIV World Congress of Gynecology and Obstetrics. New York, NY, Parthenon Publishing Group, 1994:337-342.
3. United Nations Department of International and Social Affairs. Demographic yearbook, 1985. New York, NY, United Nations, 1987.
4. Research on the menopause. Report of a WHO Scientific Group. Geneva, World Health Organization, 1981 (WHO Technical Report Series, No. 670).
5. Agoestina T, Keep PA. The climacteric in Bandung, West Java Province, Indonesia. A survey of 1025 women between 40-55 years of age. Maturitas, 1984, 16:327-334.
6. Martin MC et al. Menopause without symptoms: the endocrinology of menopause among rural Mayan Indians. American journal of obstetrics and gynecology, 1993, 168:1839-1845.
7. Kaufert P, McKinlay SM. Estrogen replacement therapy: the production of medical knowledge and the emergence of policy. In: Lewin E, Diesen V, eds. Women, health and healing. New York, NY, Tavistock Publications, 1985:113-138.
8. Lock M. Encounters with aging: mythologies of menopause in Japan and North America. Berkeley, CA, University of California Press, 1993.
9. Hill K. The demography of menopause. Maturitas, 1996, 23:113-127.
10. World health statistics annual 1993. Geneva, World Health Organization, 1994.
11. The International Classification of Diseases. Ninth revision: Basic Tabulation List with Alphabetical Index. Geneva, World Health Organization, 1978.
12. Burger HG. The endocrinology of the menopause. Maturitas, 1996, 23:129-136.
13. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. American journal of human biology, 1992, 4:37-46.
14. McKinlay SM. The normal menopause transition: an overview. Maturitas, 1996, 23:137-145.
15. Block E. A quantitative morphological investigation of the follicular system in newborn female infants. Acta anatomica, 1953, 17:201-206.
16. Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proceedings of the Royal Society of London, Series B: Biological Sciences, 1963, 158:417-433.
17. Gougeon A. Caractère qualitatif et quantitatif de la population folliculaire dans l'ovaire humain adulte. [Qualitative and quantitative characteristics of the follicular cell population in the adult human ovary.] Contraception - fertilité - sexualité, 1984, 12:527-535.
18. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. Journal of clinical endocrinology and metabolism, 1987, 65:1231-1237.
19. Block E. Quantitative morphological investigation of the follicular systems in women. Acta anatomica, 1952, 14:108-123.
20. Treloar AE et al. Variation of the human menstrual cycle through reproductive life. International journal of fertility, 1967, 12:77-126.
21. Brambilla DJ, McKinlay SM. A prospective study of factors affecting age at menopause. Journal of clinical epidemiology, 1989, 42:1031-1039.
22. Richardson SJ. The biological basis of the menopause. Baillière's clinical endocrinology and metabolism, 1993, 7:1-16.
23. Stanford JL et al. Factors influencing the age at natural menopause. Journal of chronic diseases, 1987, 40:995-1002.
24. Snowdon DA et al. Is early natural menopause a biological marker of health and ageing? American journal of public health, 1989, 79:709-714.
25. Snowdon DA. Early natural menopause and the duration of postmenopausal life. Journal of the American Geriatrics Society, 1990, 38:402-408.
26. Beall CM. Ages at menopause and menarche in a high-altitude Himalayan population. Annals of human biology, 1983, 10:365-370.
27. Payer L. Menopause in various cultures. In: Burger H, Boulet M, eds. A portrait of the menopause. Carnforth, Parthenon Publishing Group, 1991:3-22.
28. Johnson PL, Wood JW, Weinstein M. Female fecundity in highland Papua New Guinea. Social biology, 1990, 37:26-43.
29. Goodman MJ et al. Menarche, pregnancy, birth spacing and menopause among the Agta women foragers of Cagayan Province, Luzon, the Philippines. Annals of human biology, 1985, 12:169-177.
30. Okonofua FE, Lawal A, Bamgbose J. Features of menopause and menopausal age in Nigerian women. International journal of gynecology and obstetrics, 1990, 31:341-345.
31. Kwawukume EY, Ghosh TS, Wilson JB. Menopausal age of Ghanaian women. International journal of gynecology and obstetrics, 1993, 40:151-155.
32. Randhawa I, Premi HK, Gupta T. The age at menopause in the women of Himachal Pradesh, and the factors affecting menopause. Indian journal of public health, 1987, 31:40-44.
33. Wasti S et al. Characteristics of menopause in three socioeconomic urban groups in Karachi, Pakistan. Maturitas, 1993, 16:61-69.
34. Sukwatana P et al. Menopausal symptoms among Thai women in Bangkok. Maturitas, 1991, 13:217-228.
35. Chompootweep S et al. The menopausal age and climacteric complaints in Thai women in Bangkok. Maturitas, 1993, 17:63-71.
36. McKinlay SM. Issues in design, measurement, and analysis for menopause research. Experimental gerontology, 1994, 29:479-493.
37. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. Journal of clinical investigation, 1975, 55:699-706.
38. Reyes FI, Winter JSD, Faiman C. Pituitary-ovarian relationships preceding the menopause. American journal of obstetrics and gynecology, 1977, 129:557-564.
39. Lee SJ et al. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles. Human reproduction, 1988, 3:851-855.
40. Lenton EA et al. Progressive changes in LH and FSH and LH:FSH ratio in women throughout reproductive life. Maturitas, 1988, 10:35-43.
41. MacNaughton J et al. Age-related changes in follicle-stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age. Clinical endocrinology, 1992, 36:339-345.
42. Lenton EA et al. Inhibin concentrations throughout the menstrual cycles of normal, infertile and older women compared with those during spontaneous conception cycles. Journal of clinical endocrinology and metabolism, 1991, 73:1180-1190.
43. Metcalf MG, Donald RA. Fluctuating ovarian function in a perimenopausal woman. New Zealand medical journal, 1979, 89:45-47.
44. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition. Clinical endocrinology, 1981, 14:245-255.
45. Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition - an analysis of FSH, oestradiol and inhibin. European journal of endocrinology, 1994, 130:38-42.
46. Chakravarti S et al. Hormonal profiles after the menopause. British medical journal, 1976, 2:784-787.
47. Wide L et al. Radioimmunosorbent assay of follicle-stimulating hormone and luteinizing hormone in serum and urine from men and women. Acta endocrinologica, 1973, 174:3-58.
48. Kwekkeboom DJ et al. Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women. Journal of clinical endocrinology and metabolism, 1990, 70:944-950.
49. Rossmanith WG, Scherbaum WA, Lauritzen C. Gonadotropin secretion during aging in postmenopausal women. Neuroendocrinology, 1991, 54:211-218.
50. Healy DL et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumours. New England journal of medicine, 1993, 329:1539-1542.
51. Sitteri PK, MacDonald PC. Role of extraglandular estrogen in human endocrinology. In: Greep RO, Astwood EB, eds. Handbook of physiology, Vol. 2, Part 1. Baltimore, MD, Williams & Wilkins, 1973:615-629.
52. Cauley JA et al. Reliability and interrelations among serum sex hormones in postmenopausal women. American journal of epidemiology, 1991, 133:50-57.
53. Hughes CL, Jr, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecologic oncology, 1991, 40:42-45.
54. Procope B. Studies on the urinary excretion, biological effects and origin of oestrogens in postmenopausal women. Acta endocrinologica, 1969, 135:5-110.
55. Utian WH. Circulating estrogens and their sources at the perimenopause. In: Genazzani AR, Petraglia F, eds. Hormones in gynecological endocrinology. New Jersey, Parthenon Publishing Group, 1992:505-512.
56. Meldrum DR et al. Changes in circulating steroids with ageing in postmenopausal women. Obstetrics and gynecology, 1981, 57:624-628.
57. Panico S et al. Diurnal variation of testosterone and estradiol: a source of bias in comparative studies on breast cancer. Journal of endocrinological investigation, 1990, 13:423-426.
58. Lonning PE et al. Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. Journal of steroid biochemistry, 1989, 34:551-553.
59. Micheli A et al. Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women. Journal of clinical epidemiology, 1991, 44:1055-1061.
60. Anderson DC. Sex hormone-binding globulin. Clinical endocrinology, 1974, 3:69-96.
61. Rosner W. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: recent advances. Endocrine reviews, 11:80-91.
62. Carlstrom K et al. Relationship between serum testosterone and sex hormone-binding globulin in menstruating and postmenopausal women. Gynecological endocrinology, 1991, 5:95-100.
63. Reid IR et al. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. Journal of clinical endocrinology and metabolism, 1992, 75:45-51.
64. Gershagen S et al. Decreasing serum levels of sex hormone-binding globulin around the menopause and temporary relation to changing levels of ovarian steroids, as demonstrated in a longitudinal study. Fertility and sterility, 1989, 51:616-621.
65. Akingbade OA, Bolarinwa AF, Subbarao W. Symptomatology and hormone profile of menopausal Nigerians. African journal of medicine and medical sciences, 1990, 19:133-137.
66. Wang DY et al. Serum hormone levels in British and rural Chinese females. Breast cancer research and treatment, 1991, 18(Suppl.):S41-S45.
67. Cauley JA et al. The epidemiology of serum sex hormones in postmenopausal women. American journal of epidemiology, 1989, 129:1120-1131.
68. Kaufert PA. Women and their health in middle years: a Manitoba project. Social science and medicine, 1984, 18:279-281.
69. Holte A. Prevalence of climacteric complaints in a representative sample of middle-aged women in Oslo, Norway. Journal of psychosomatic obstetrics and gynaecology, 1991, 12:303-317.
70. Oldenhave A, Jaszmann LJB. The climacteric: absence or presence of hot flushes and their relation to other complaints. In: Schonbaum E, ed. The climacteric hot flush. Basel, Karger, 1991 (Progess in Basic Clinical Pharmacology, Vol. 6):6-39.
71. Oldenhave A, Jaszmann LJB. The climacteric: absence or presence of hot flushes and their relation to other complaints. In: Schonbaum E, ed. The climacteric hot flush. Basel, Karger, 1991 (Progess in Basic Clinical Pharmacology, Vol. 6):6-39.
72. Dennerstein L et al. Sexuality and the menopause. Journal of psychosomatic obstetrics and gynaecology, 1993, 15:59-66.
73. Matthews KA et al. Influences of natural menopause on psychological characteristics and symptoms of middle-aged healthy women. Journal of consulting and clinical psychology, 1990, 58:345-351.
74. Holte A. Influences of natural menopause on health complaints: a prospective study of healthy Norwegian women. Maturitas, 1992, 14:127-141.
75. Hunter MS. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas, 1992, 14:117-126.
76. Kaufert PA, Gilbert P, Tate R. The Manitoba Project: a re-examination of the link between menopause and depression. Maturitas, 1992, 14:143-155.
77. Greene JG, Cooke DJ. Life stress and symptoms at the climacterium. British journal of psychiatry, 1980, 136:486-491.
78. Holte A, Mikkelsen A. A factor-analytic study of climacteric symptoms. Psychiatry and social science, 1982, 2:35-39.
79. Ballinger CB. Psychiatric aspects of the menopause. British journal of psychiatry, 1990, 156:773-787.
80. Hunter MS. Emotional well-being, sexual behaviour and hormone replacement therapy. Maturitas, 1990, 12:299-314.
81. Erlik Y et al. Association of waking episodes with menopausal hot flushes. Journal of the American Medical Association, 1981, 245:1741-1744.
82. Wentz AC. Management of the menopause. In: Jones HW, Wentz AC, Burnett LS, eds. Novak's textbook of gynecology, 11th ed. Baltimore, MD, Williams & Wilkins, 1988:394-442.
83. Ginsburg J, Swinhoe J, O'Reilly B. Cardiovascular responses during the menopausal hot flush. British journal of obstetrics and gynaecology, 1981, 88:925-930.
84. Meldrum DR et al. Objectively recorded hot flushes in patients with pituitary insufficiency. Journal of clinical endocrinology and metabolism, 1981, 52:684-688.
85. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteinizing hormone secretion. Science, 1979, 205:823-825.
86. Tataryn IV et al. LH, FSH and skin temperature during the menopausal hot flush. Journal of clinical endocrinology and metabolism, 1979, 49:152-154.
87. Beyenne Y. From menarche to menopause: reproductive lives of peasant women in two cultures. Albany, NY, State University of New York Press, 1986.
88. Avis NE et al. The evolution of menopausal symptoms. Baillière's clinical endocrinology and metabolism, 1993, 7:17-32.
89. Tang GWK. Menopausal symptoms. Journal of the Hong Kong Medical Association, 1993, 45:249-254.
90. Dennerstein L et al. Menopausal symptoms in Australian women. Medical journal of Australia, 1993, 159:232-236.
91. Sturdee D, Brincat M. The hot flush. In: Studd JWW, Whitehead MI, eds. The menopause. London, Blackwell Scientific, 1988:24-54.
92. Haines CJ, Chung TKH, Leung DHY. A prospective study of the frequency of acute menopausal symptoms in Hong Kong Chinese women. Maturitas, 1994, 18:175-181.
93. Hagstad A, Janson PO. The epidemiology of climacteric symptoms. Acta obstetricia et gynecologica Scandinavica, 1986, 134(Suppl.):59-65.
94. van Hall EV, Verdel M, van der Velden J. Perimenopausal complaints in women and men: a comparative study. Journal of women's health, 1994, 3:45-49.
95. Adlercreutz H et al. Dietary phyto-oestrogens and the menopause in Japan. Lancet, 1992,339:1233.
96. Wilcox G et al. Oestrogenic effects of plant foods in postmenopausal women. British medical journal, 1990, 301:905-906.
97. McKínlay JB, McKínlay SM, Brambílla D. The relatíve contríbutions of endocrine changes and social circumstances to depression in mid-aged women. Journal of health and social behavior, 1987, 28:345-363.
98. Coope J, Williams S, Patterson JS. A study of the effectiveness of propanolol in menopausal hot flushes. British journal of obstetrics and gynaecology, 1978, 85:472-475.
99. Kronenberg F, Barnard RM. Modulation of menopausal hot flushes by ambient temperature. Journal of thermal biology, 1992, 17:43-49.
100. Utian WH. The true clinical features of postmenopause and oophorectomy and their response to oestrogen therapy. South African medical journal, 1972, 46:732-737.
101. Bullock JL et al. Use of medroxy-progesterone acetate to prevent menopausal symptoms. Obstetrics and gynecology, 1975, 46:165-168.
102. Coope J, Thomson J. Effects of "natural oestrogens" on menopausal symptoms and blood clotting. British medical journal, 1975, 4:139-143.
103. Campbell S. Double-blind psychometric studies on the effects of natural estrogens on the postmenopausal woman. In: Campbell S, ed. The management of the menopause and postmenopausal years. Lancaster, MTP Press, 1976:149-158.
104. Campbell S et al. Oestrogens for menopausal flushing. British medical journal, 1977, 2:1218-1219.
105. Cagnacci A et al. Neuroendocrine and clinical effects of transdermal 17beta-estradiol in postmenopausal women. Maturitas, 1991, 13:283-296.
106. Dupont A et al. Efficacy of percutaneous estradiol and oral estrogens as replacement therapy in postmenopausal women. In: Dusitsin N, Notelovitz M, eds. Physiological hormone replacement therapy. Carnforth, Parthenon Publishing Group, 1991:37-49.
107. Keller PJ, Hotz E, Imthurn B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas, 1992, 15:195-198.
108. Steingold KA et al. Treatment of hot flushes with transdermal estradiol administration. Journal of clinical endocrinology and metabolism, 1985, 61:627-632.
109. Høvik P et al. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas, 1989, 11:75-82.
110. Hammar M, Berg C, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Acta obstetricia et gynecologica Scandinavica, 1990, 69:409-412.
111. Freedman BR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. American journal of obstetrics and gynecology, 1992, 167:436-439.
112. Gordon H. The correlation of menopausal symptoms with cytohormonal status. In: Campbell S, ed. The management of the menopause and postmenopausal years. Lancaster, MTP Press, 1976:263-270.
113. Coope J. Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas, 1996, 23:159-168.
114. Marsh MS, Whitehead MI. Management of the menopause. In: Khaw KT, ed. Hormone replacement therapy. Edinburgh, Churchill Livingstone, 1992: 426-457.
115. Coope J. The effect of oestrogen therapy in menopausal patients [Dissertation]. Manchester, UK, University of Manchester Medical School, 1980.
116. Ellerington M, Whitcroft S, Whitehead MI. A double-blind, randomised, cross-over comparison of a bioadhesive vaginal moisturising gel and KY jelly in post menopausal women with vaginal dryness despite HRT. Sixth congress on the menopause, Bangkok. Carnforth, Parthenon Publishing Group, 1990, Abstract 335.
117. Bachmann GA et al. Sexual expression and its determinants in the postmenopausal woman. Maturitas, 1984, 6:19-29.
118. Pfeiffer E, Verwoendt A, Davis GC. Sexual behaviour in middle life. American journal of psychiatry, 1972, 128:1262-1267.
119. Carney A, Bancroft J, Matthews A. Combination of hormonal and psychological treatment for female sexual unresponsiveness: a comparative study. British journal of psychiatry, 1978, 133:339-346.
120. Leiblum S et al. Vaginal atrophy in the postmenopausal woman. Journal of the American Medical Association, 1983, 249:2195-2198.
121. Burger H et al. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. British medical journal, 1987, 294:936-937.
122. Jolleys JV. Repeated prevalence of urinary incontinence in women in a general practice. British medical journal, 1988, 296:1300-1302.
123. Yarnell JW et al. The prevalence and severity of urinary incontinence in women. Journal of epidemiology and community health, 1981, 35:71-74.
124. Diokno AC et al. Prevalence of urinary incontinence and other urological symptoms in the non-institutionalized elderly. Journal of urology, 1986, 136:1022-1025.
125. Rekers H et al. The menopause, urinary incontinence and other symptoms of the genito-urinary tract. Maturitas, 1992, 15:101-111.
126. Smith P et al. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas, 1993, 16:145-154.
127. Bacho C, Winandy A. Étude préliminaire de l'influence hormonale sur les différents paramètres du plancher pelvien chez la femme en activité génitale sans hormonothérapie et chez la femme ménopausée. [Preliminary study of the hormonal effect on various parameters of the pelvic floor in genitally active women without hormone therapy and in menopausal women.] Acta urologica belgique, 1992, 60:45-60.
128. Wilson PD et al. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. British journal of obstetrics and gynaecology, 1987, 94:568-574.
129. Raz R, Stamm WE. A controlled trial of intra-vaginal estriol in postmenopausal women with recurrent urinary tract infections. New England journal of medicine, 1993, 329:753-756.
130. Metcalf MG. The approach of menopause: a New Zealand study. New Zealand medical journal, 1988, 101:103-106.
131. Hee J et al. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. Maturitas, 1993, 18:9-20.
132. Thompson B, Hart SA, Durno D. Menopausal age and symptomatology in a general practice. Journal of biosocial science, 1973, 5:71-82.
133. McKinlay SM, Jefferys M. The menopausal syndrome. British journal of preventive and social medicine, 1974, 28:108-115.
134. Avis NE, McKinlay SM. A longitudinal analysis of women's attitudes towards the menopause: results from the Massachusetts Women's Health Study. Maturitas, 1991, 13:65-79.
135. Hunter MS, Battersby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas, 1986, 8:217-228.
136. Dennerstein L et al. Hormone therapy and affect. Maturitas, 1979, 1:247-259.
137. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, cross-over study of sex steroid administration in the surgical menopause. Psychosomatic medicine, 1985, 47:339-351.
138. Montgomery JC et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet, 1987, i:297-299.
139. Dennerstein L, Burrows GD. Psychological effects of progestogens in the postmenopausal years. Maturitas, 1986, 8:101-106.
140. Lock M. Contested meanings of the menopause. Lancet, 1991, 337:1270-1272.
141. Midlife and older women in Latin America and the Caribbean. Washington, DC, Pan American Health Organization, 1989.
142. Kaufert PA. The social and cultural context of menopause. Maturitas, 1996, 23:169-180.
143. Rutter M. Women's health in developing countries. Nursing, 1988, 25:935-936.
144. Sadik N. The state of the world's population 1991. New York, United Nations Population Fund, 1991.
145. Bauer RL et al. Risk of postmenopausal hip fracture in Mexican American women. American journal of public health, 1986, 76:1020-1021.
146. Ross PD et al. A comparison of hip fracture incidence among native Japanese, Japanese Americans and American Caucasians. American journal of epidemiology, 1991, 133:801-809.
147. Sergent C. Maternity, medicine and power: reproductive decisions in urban Benin. Berkeley, CA, University of California Press, 1989.
148. Lee RB. Work, sexuality, and ageing among Kung women. In: Kerns V, Brown JK, eds. In her prime, 2nd ed. Chicago, IL, University of Illinois Press, 1992:35-48.
149. Solway JS. Middle-aged women in Bakgalagadi society (Botswana). In: Kerns V, Brown JK, eds. In her prime, 2nd ed. Chicago, IL, University of Illinois Press, 1992:49-60.
150. Kerns V. Female control of sexuality: Garifuna women at middle age. In: Kerns V, Brown JK, eds. In her prime, 2nd ed. Chicago, IL, University of Illinois Press, 1992:95-112.
151. Shaaban MM. The perimenopause and contraception. Maturitas, 1996, 23:181-192.
152. Trussell J, Westoff CF. Contraceptive practice and trends in coital frequency. Family planning perspectives, 1980, 12:246-249.
153. Gray RH. Biological and social interaction in the determination of late fertility. Journal of biosocial science, 1979, 6(Suppl.):97-115.
154. van Keep PA, Kellerhals JM. Consensus on menopause research. Lancaster, UK, MTP Press, 1976.
155. Doring GK. The incidence of anovulatory cycles of women. Journal of reproduction and fertility, 1969, 6(Suppl.):77-81.
156. Kaufman SA. Fertility and contraception after the age of forty. Obstetrics and gynecology, 1969, 3:288-291.
157. Navot D et al. Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility. Lancet, 1991, 337:1375-1377.
158. Schwartz D, Mayaux MJ. Female fecundity as a function of age. Federation CECOS. New England journal of medicine, 1982, 306:404-406.
159. Baird DD, Wilcox AJ. Cigarette smoking associated with delayed conception. Journal of the American Medical Association, 1985, 253:2979-2983.
160. Buehler JW et al. Maternal mortality in women aged 35 years or older in the United States. Journal of the American Medical Association, 1986, 255:53-57.
161. Jansen RP. Fertility in older women. International Planned Parenthood Federation (IPPF) medical bulletin, 1984, 18:4-6.
162. Guillebaud J. Contraception for women over 35 years of age. British journal of family planning, 1992, 17:115-118.
163. Abdullah SA et al. Maternal mortality in Assiut. International journal of gynecology and obstetrics, 1992, 39:197-204.
164. Upton GV, Corbin A. Contraception for the transitional years of women older than 40 years of age. Clinical obstetrics and gynecology, 1992, 35:855-864.
165. Wharton C, Blackburn R. Oral contraceptives. Population reports, series A: oral contraceptives, 1988, 7:1-31.
166. Vessey MR Female hormones and vascular disease - an epidemiological overview. British journal of family planning, 1980, 6:1-12.
167. Stadel BV. Oral contraceptives and cardiovascular disease. New England journal of medicine, 1981, 305:612-618, 672-677.
168. Mishell DR. Use of oral contraceptives in women of older reproductive age. American journal of obstetrics and gynecology, 1988, 158:1652-1657.
169. Colditz GA. Oral contraceptive use and mortality during 12 years of follow-up: the Nurses' Health Study. Annals of internal medicine, 1994, 120:821-826.
170. Thorogood M et al. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. British journal of obstetrics and gynaecology, 1991, 98:1245-1253.
171. Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstetrics and gynecology, 1987, 70:29-32.
172. Mant D et al. Myocardial infarction and angina pectoris in young women. Journal of epidemiology and community health, 1987, 41:215-219.
173. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. British medical journal, 1993, 306:956-963.
174. Thorogood M et al. Fatal stroke and use of oral contraceptives: findings from a case-control study. American journal of epidemiology, 1992, 136:35-45.
175. Thorogood M et al. Risk factors for fatal venous thromboembolism in young women: a case-control study. International journal of epidemiology, 1992, 21:48-52.
176. WHO Collaborative Study. Cardiovascular disease and use of oral contraceptives. Bulletin of the World Health Organization, 1989, 67:417-423.
177. Luukkainen T. Contraception after thirty-five. Acta obstetricia et gynecologica Scandinavica, 1992, 71:169-174.
178. Khaw KT, Peart WS. Blood pressure and contraceptive use. British medical journal, 1982, 285:403-407.
179. Task Force on Oral Contraceptives. WHO Special Programme of Research, Development and Research Training in Human Reproduction. A multicentre study of coagulation and haemostatic variables during oral contraception. Variations with four formulations. British journal of obstetrics and gynaecology, 1991, 98:1117-1128.
180. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiologic reviews, 1993, 15:80-97.
181. Wingo PA et al. Age-specific differences in the relationship between oral contraceptive use and breast cancer. Obstetrics and gynecology, 1991, 78:161-170.
182. Yuan JM et al. Risk factors for breast cancer in Chinese women in Shanghai. Cancer research, 1988, 48:1949-1953.
183. Vessey MP et al. An epidemiological study of oral contraceptives and breast cancer. British medical journal, 1979, 1:1757-1760.
184. Skegg DCG. The epidemiological assessment of the safety of hormonal contraceptives: a methodological review. In: Michal F, ed. Safety requirements for contraceptive steroids. Cambridge, Cambridge University Press, 1989:21-37.
185. Stanford JL et al. Oral contraceptives and breast cancer: results from an expanded case-control study. British journal of cancer, 1989, 60:375-381.
186. Romieu I et al. Prospective study of oral contraceptive use and risk of breast cancer in women. Journal of the National Cancer Institute, 1989, 81:1313-1321.
187. Oral contraceptives and neoplasia. Report of a WHO Scientific Group. Geneva, World Health Organization, 1992 (WHO Technical Report Series, No. 817).
188. Mehta S. Oral contraception - benefits and risks. In: Senanayoke P, Kleinman R, eds. Family planning, meeting challenges: promoting choices. Carnforth, Parthenon Publishing Group, 1993:463-476.
189. Chi I. The safety and efficacy issues of progestin-only oral contraceptives - an epidemiological perspective. Contraception, 1993, 47:1-21.
190. Cundy T et al. Bone density in women receiving depot-medroxyprogesterone acetate for contraception. British medical journal, 1991, 303:13-16.
191. World Health Organization. Depot-medroxyprogesterone acetate (DMPA) and cancer. Memorandum from a WHO meeting. Bulletin of the World Health Organization, 1993, 71:669-676.
192. Shaaban MM et al. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels. Fertility and sterility, 1993, 59:998-1002.
193. Farley TM et al. Intrauterine device and pelvic inflammatory disease: an international perspective. Lancet, 1992, 339:785-788.
194. Luukkainen T et al. Five years' experience of intrauterine contraception with Nova T and the Copper-T-200. American journal of obstetrics and gynecology, 1983, 147:885-892.
195. Kozuh-Novak M, Andolsek L. IUD use after 40 years of age. Advances in contraception, 1988, 4:85-94.
196. Luukkainen T et al. Intra-uterine release of levonorgestrel. In: Zatuchni GI et al., eds. Long-acting contraceptive delivery systems. Philadelphia, Harper & Row, 1984:601-612.
197. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstetrics and gynecology, 1991, 77:261-264.
198. Vessey M, Lawless M, Yeates D. Efficacy of different contraceptive methods. Lancet, 1982, i:841-842.
199. Stone KM, Grimes DA, Magder LS. Personal protection against sexually transmitted diseases. American journal of obstetrics and gynecology, 1986, 155:180-188.
200. Austin H, Louv WC, Alexander WJ. A case-control study of spermicides and gonorrhea. Journal of the American Medical Association, 1984, 251:2822-2824.
201. Conant M et al. Condoms prevent transmission of AIDS-associated retrovirus. Journal of the American Medical Association, 1986, 255:1706.
202. Feldblum PJ, Weir SS. The protective effect of nonoxynol-9 against HIV infection. American journal of public health, 1984, 84:1032-1034.
203. Liskin L et al. Minilaparotomy and laparoscopy: safe, effective and widely used. Population reports, series C: female sterilization, 1985, 9:125-167.
204. Hankinson SE. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. Journal of the American Medical Association, 1993, 270:2813-2818.
205. Flynn AM. Symptothermal and hormonal markers of potential fertility in climacteric women. American journal of obstetrics and gynecology, 1991, 165:1987-1989.
206. Metcalf MG. Incidence of ovulatory cycles in women approaching the menopause. Journal of biosocial science, 1979, 11:39-48.
207. Royston E, Armstrong S, eds. Preventing maternal deaths. Geneva, World Health Organization, 1989.
208. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, World Health Organization, 1994 (WHO Technical Report Series, No. 843).
209. Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. American journal of medicine, 1987, 82(Suppl. 1b):68-72.
210. Compston JE. Structural mechanisms of trabecular bone loss. In: Smith R, ed. Osteoporosis. London, Royal College of Physicians, 1990:35-43.
211. Spotila LD et al. Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88:5423-5427.
212. Melton LJ III et al. Perspective. How many women have osteoporosis? Journal of bone and mineral research, 1992, 7:1005-1010.
213. Peck WA et al. Research directions in osteoporosis. American journal of medicine, 1988, 84:275-282.
214. Kelsey JL, Hoffman S. Risk factors for hip fracture. New England journal of medicine, 1987, 316:404-406.
215. Poor G, Jacobsen SJ, Melton LJ III. Mortality following hip fracture. In: Vellas BJ, Albarede JL, Garry PJ, eds. Facts and research in gerontology. Paris, Serdi, 1994:91-109.
216. Chrischilles EA et al. A model of lifetime osteoporosis impact. Archives of internal medicine, 1991, 151:2026-2032.
217. Solomon L. Osteoporosis and fracture of femoral neck in the South African Bantu. Journal of bone and joint surgery (British), 1968, 50:2-13.
218. Nordin BE. International patterns of osteoporosis. Clinical orthopaedics and related research, 1966, 45:17-30.
219. Trotter M, Broman GE, Peterson RR. Densities of bones of white and negro skeletons. Journal of bone and joint surgery (American), 1960, 42A:50-58.
220. Cohn SH et al. Comparative skeletal mass and radial bone mineral content in black and white women. Metabolism: clinical and experimental, 1977, 26:171-178.
221. Garn SM, Pao EM, Rihl ME. Compact bone in Chinese and Japanese. Science, 1964, 143:1439-1440.
222. Yano K et al. Bone mineral measurements among middle-aged and elderly Japanese residents in Hawaii. American journal of epidemiology, 1984, 119:751-764.
223. Gallagher JC et al. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. Clinical orthopaedics and related research, 1980, 150:163-171.
224. Cummings SR et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiologic reviews, 1985, 7:178-208.
225. Bloom RA, Pogrund H. Humeral cortical thickness in female Bantu - its relationship to the incidence of femoral neck fracture. Skeletal radiology, 1982, 8:59-62.
226. Mehta S. Bone loss, contraception and lactation. Acta obstetricia et gynecologica Scandinavica, 1993, 72:148-156.
227. Lau EMC. Hip fracture in Asia - trends, risk factors and prevention. In: Christiansen C, Riis B, eds. Osteoporosis proceedings, 1993. Rodovre, Fourth International Symposium on Osteoporosis, 1993:58-61.
228. Melton LJ III, O'Fallon WM, Riggs BL Secular trends in the incidence of hip fractures. Calcified tissue international, 1987, 41:57-64.
229. Melton LJ III, Riggs BL. Epidemiology of age-related fractures. In: Avioli LV, ed. The osteoporotic syndrome: detection, prevention and treatment. New York, NY, Grune and Stratton, 1983:45-72.
230. Johnell O et al. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis international, 1992, 2:298-302.
231. Cooper C et al. Incidence of clinical diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. Journal of bone and mineral research, 1992, 7:221-227.
232. Riggs BL, Melton LJ III. Involutional osteoporosis. New England journal of medicine, 1986, 314:1676-1686.
233. Gilsanz V et al. Vertebral bone density in children: effect of puberty. Radiology, 1988, 166:847-850.
234. Glastre C et al. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. Journal of clinical endocrinology and metabolism, 1990, 70:1330-1333.
235. Theintz G et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents; evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of clinical endocrinology and metabolism, 1992, 75:1060-1065.
236. Mazess RB. On aging bone loss. Clinical orthopaedics and related research, 1982, 165:239-252.
237. Kelly PJ et al. Sex differences in peak adult bone mineral density. Journal of bone and mineral research, 1990, 5:1169-1175.
238. Ott SM. Bone density in adolescents. New England journal of medicine, 1991, 325:1646-1647.
239. Wark JD. Osteoporosis: pathogenesis, diagnosis, prevention and management. Baillière's clinical endocrinology and metabolism, 1993, 7:151-181.
240. Hui SL et al. A prospective study of change in bone mass with age in postmenopausal women. Journal of chronic diseases, 1982, 35:715-725.
241. Murphy S et al. Endogenous sex hormones and bone mineral density among community-based postmenopausal women. Postgraduate medical journal, 1992, 68:908-913.
242. Steinberg KK et al. Sex steroids and bone density in premenopausal and perimenopausal women. Journal of clinical endocrinology and metabolism, 1989, 69:533-539.
243. Slemenda C et al. Sex steroids and bone mass. A study of changes about the time of menopause. Journal of clinical investigation, 1987, 80:1261-1269.
244. Spector TD. The relationship between sex steroids and bone mineral content in women soon after the menopause. Clinical endocrinology, 1991, 34:37-41.
245. Morrison NA et al. Prediction of bone density from vitamin D receptor alleles. Nature, 1994, 367:284-287.
246. Frost HM. Mechanical microdamage, bone remodelling and osteoporosis: a review. In: Deluca HF et al., eds. Osteoporosis: recent advances in pathogenesis and treatment. Baltimore, MD, University Park Press, 1981:185-190.
247. Johnston CC, Slemenda CW. Risk assessment: theoretical considerations. American journal of medicine, 1993, 95(Suppl. 5a):2-5.
248. Faulkner KG et al. Simple measurement of femoral geometry. Journal of bone and mineral research, 1993, 8:1211-1217.
249. Ross PD et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Annals of internal medicine, 1991, 114:919-923.
250. Gibson MJ. The prevention of falls in later life. Danish medical bulletin, 1987, 34:1-24.
251. Ray WA et al. Psychotropic drug use and the risk of hip fracture. New England journal of medicine, 1987, 316:363-368.
252. Black DM et al. Axial and appendicular bone density predict fractures in older women. Journal of bone and mineral research, 1992, 7:633-638.
253. Ross PD, Wasnich RD, Vogel JM. Detection of prefracture spinal osteoporosis using bone mineral densitometry. Journal of bone and mineral research, 1988, 3:1-11.
254. Eastell R et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. Journal of clinical investigation, 1989, 83:168-174.
255. Cummings SR et al. Bone density at various sites for prediction of hip fractures: the Study of Osteoporotic Fractures Research Group. Lancet, 1993, 341:72-75.
256. Kelly TL et al. Quantitative digital radiography versus dual photon absorptiometry of the lumbar spine. Journal of clinical endocrinology and metabolism, 1988, 67:839-844.
257. Cummings SR. Position papers. Bone mineral densitometry. Annals of internal medicine, 1987, 107:932-936.
258. Agren M et al. Ultrasound attenuation of the calcaneus: a sensitive and specific discriminator of osteopenia in postmenopausal women. Calcified tissue international, 1991, 48:240-244.
259. Salamone LM et al. Comparison of broadband ultrasound attenuation to single X-ray absorptiometry measurements at the calcaneus in postmenopausal women. Calcified tissue international, 1994, 54:87-90.
260. Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet, 1987, i:1105-1107.
261. Robins SR An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochemical journal, 1982, 207:617-620.
262. Eyre DR, Koob TJ, van Ness KR Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Analytical biochemistry, 1984, 137:380-388.
263. Uebelhart D et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone and mineral, 1990, 8:87-96.
264. Uebelhart D et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. Journal of clinical endocrinology and metabolism, 1991, 72:367-373.
265. Delmas PD et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. Journal of bone and mineral research, 1991, 6:639-644.
266. Hanson DA et al. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopeptides in urine. Journal of bone and mineral research, 1992, 7:1251-1258.
267. Johnston CC et al. Calcium supplementation and increases in bone mineral density in children. New England journal of medicine, 1992, 327:82-87.
268. Lloyd T et al. Calcium supplementation and bone mineral density in adolescent girls. Journal of the American Medical Association, 1993, 270:841-844.
269. Heaney RP. Bone mass, nutrition and other lifestyle factors. American journal of medicine, 1993, 95(Suppl. 5a):29-33.
270. Dawson-Hughes B et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. New England journal of medicine, 1990, 323:878-883.
271. 3 and calcium to prevent hip fractures in elderly women. New England journal of medicine, 1992, 327:1637-1642.
272. Reid IR et al. Effect of calcium supplementation on bone loss in postmenopausal women. New England journal of medicine, 1993, 328:460-464.
273. Elders PJM et al. Calcium supplementation reduces vertebral bone loss in perimenopausal women: a controlled trial in 248 women between 46 and 55. Journal of clinical endocrinology and metabolism, 1991, 73:533-540.
274. Consensus conference: osteoporosis. Journal of the American Medical Association, 1984, 252:799-802.
275. Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. Journal of laboratory and clinical medicine, 1978, 92:953-963.
276. Charles P. Metabolic bone disease evaluated by a combined calcium balance and tracer kinetic study. Danish medical bulletin, 1989, 36:463-479.
277. DeLuca HF. The vitamin D story: a collaborative effort of basic science and clinical medicine. FASEB journal, 1988, 2:224-236.
278. Francis RM et al. Calcium malabsorption in elderly women with vertebral fractures: evidence for resistance to the action of vitamin D metabolites on the bowel. Clinical science, 1984, 66:103-107.
279. Slovik DM et al. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. New England journal of medicine, 1981, 305:372-374.
280. Dawson-Hughes B et al. Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. Annals of internal medicine, 1991, 115:505-512.
281. Heikinheimo RJ et al. Annual injection of vitamin D and fractures of aged bones. Calcified tissue international, 1992, 51:105-110.
282. Parfitt AM et al. Vitamin D and bone health in the elderly. American journal of clinical nutrition, 1982, 36:1014-1031.
283. Chesnut CH. Bone mass and exercise. American journal of medicine, 1993, 95(Suppl. 5a):34-36.
284. Notelovitz M et al. Estrogen therapy and variable-resistance weight training increase bone mineral in surgically menopausal women. Journal of bone and mineral research, 1991, 6:583-590.
285. Krolner B et al. Physical exercise as prophylaxis against involutional vertebral bone loss: a controlled trial. Clinical science, 1983, 64:541 -546.
286. Donaldson CL et al. Effect of prolonged bed rest on bone mineral. Metabolism: clinical and experimental, 1970, 19:1071-1084.
287. Vogel JM et al. Bone mineral measurement: experiment MO78. In: Johnston RS, Dietlein LF, eds. Biomedical results from Skylab. Washington, DC, Scientific and Technical Information Office, National Aeronautics and Space Administration, 1977:183-190.
288. Drinkwater BL et al. Bone mineral content of amenorrheic and eumenorrheic athletes. New England journal of medicine, 1984, 311:277-281.
289. Prince RL et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. New England journal of medicine, 1991, 325:1189-1195.
290. Kirk S et al. Effect of long-distance running on bone mass in women. Journal of bone and mineral research, 1989, 4:515-522.
291. Gleeson PB et al. Effects of weight lifting on bone mineral density in premenopausal women. Journal of bone and mineral research, 1990, 5:153-158.
292. Drinkwater BL, Bruemner B, Chesnut CH. Menstrual history as a determinant of current bone density in young athletes. Journal of the American Medical Association, 1990, 263:545-548.
293. Krall EA, Dawson-Hughes B. Smoking and bone loss among postmenopausal women. Journal of bone and mineral research, 1991, 6:331-338.
294. Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. New England journal of medicine, 1994, 330:387-392.
295. Seeman E, Allen T. Risk factors for osteoporosis. Australian and New Zealand journal of medicine, 1989, 19:69-75.
296. Cassidenti DL et al. A re-evaluation of estrogen status in postmenopausal women who smoke. American journal of obstetrics and gynecology, 1992, 166:1444-1448.
297. Hemenway D et al. Fractures and lifestyle: effect of cigarette smoking, alcohol intake, and relative weight on the risk of hip and forearm fractures in middle-aged women. American journal of public health, 1988, 78:1554-1558.
298. Holbrook TL, Barrett-Connor E. A prospective study of alcohol consumption and bone mineral density. British medical journal, 1993, 306:1506-1509.
299. Lindsay R. Sex steroids in the pathogenesis and prevention of osteoporosis. In: Riggs BL, ed. Osteoporosis: etiology, diagnosis and management. New York, NY, Raven Press, 1988:333.
300. Lindsay R. Hormone replacement therapy for the prevention and treatment of osteoporosis. American journal of medicine, 1993, 95(Suppl. 5a):37-39.
301. Cummings SR et al. Should prescription of postmenopausal hormone therapy be based on the results of bone densitometry? Annals of internal medicine, 1990, 113:565-567.
302. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Annals of internal medicine, 1987, 106:40-45.
303. Lindsay R et al. Prevention of spinal osteoporosis in oophorectomised women. Lancet, 1980, ii:1151-1154.
304. Ettinger B, Grady D. The waning effect of post-menopausal oestrogen therapy on osteoporosis. New England journal of medicine, 1993, 329:1192-1193.
305. Felson DT et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. New England journal of medicine, 1993, 329:1141-1146.
306. Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. Journal of clinical endocrinology and metabolism, 1990, 71:836-841.
307. Genant HK et al. Effect of estrone sulfate on postmenopausal bone loss. Obstetrics and gynecology, 1990, 76:579-584.
308. Ettinger B et al. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. American journal of obstetrics and gynecology, 1992, 166:479-488.
309. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporosis international, 1991, 1:7-13.
310. Ettinger B, Genant HK. Calcium enhances the bone-sparing effects of low-dosage oestrogen in post-menopausal women. Osteoporosis international, 1993, 3(Suppl. 1):157-158.
311. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet, 1993, 341:11-13.
312. Reginster JY. Calcitonin for prevention and treatment of osteoporosis. American journal of medicine, 1993, 95(Suppl. 5a):44-47.
313. Kanis JA et al. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. British medical journal, 1992, 305:1124-1128.
314. Rico H et al. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone and mineral, 1992, 16:131-138.
315. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. American journal of medicine, 1993, 95(Suppl. 5a):48-52.
316. Storm T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New England journal of medicine, 1990, 322:1265-1271.
317. Watts NB et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. New England journal of medicine, 1990, 323:73-79.
318. Tilyard MW et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England journal of medicine, 1992, 326:357-362.
319. Orimo H et al. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone and mineral, 1987, 3:47-52.
320. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science, 1983, 222:330-332.
321. Mamelle N et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet, 1988, ii:361-365.
322. Riggs BL et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. New England journal of medicine, 1990, 322:802-809.
323. Lindsay R. Fluoride and bone - quantity versus quality. New England journal of medicine, 1990, 322:845-846.
324. Heaney RP et al. Fluoride therapy for the vertebral crush fracture syndrome. A status report. Annals of internal medicine, 1989, 111:678-680.
325. Dure-Smith BA et al. Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action. Calcified tissue international, 1991, 49(Suppl.):64-72.
326. Inkovaara JA. Is fluoride treatment justified today? Calcified tissue international, 1991, 49(Suppl.):S68-S69.
327. Tracy RE. Sex difference in coronary disease: two opposing views. Journal of chronic disease, 1966, 19:1245-1251.
328. Barrett-Connor E.The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas, 1996, 23:227-234.
329. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. Journal of the American Medical Association, 1991, 265:1861-1867.
330. Colditz GA et al. Menopause and the risk of coronary heart disease in women. New England journal of medicine, 1987, 316:1105-1110.
331. Matthews KA et al. Menopause and risk factors for coronary heart disease. New England journal of medicine, 1989, 321:641-646.
332. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas, 1990, 12:321-331.
333. Korenman SG, ed. The menopause. Biological and clinical consequences of ovarian failure: evaluation and management. (Proceedings of the Symposium on the Menopause, 5-8 March 1989, Napa, CA.) Norwell, MA, Serono Symposia USA, 1990.
334. Bush TL. Extraskeletal effects of estrogen and the prevention of atherosclerosis. Osteoporosis international, 1991, 2:5-11.
335. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive medicine, 1991, 20:47-63.
336. Grady D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of internal medicine, 1992, 117:1016-1037.
337. Psaty BM et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Archives of internal medicine, 1993, 153:1421-1427.
338. Stampfer MJ et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. New England journal of medicine, 1991, 325:756-762.
339. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. American journal of obstetrics and gynecology, 1988, 159:312-317.
340. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Archives of internal medicine, 1991, 151:75-78.
341. Falkeborn M et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. British journal of obstetrics and gynaecology, 1992, 99:821-828.
342. Hunt K et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. British journal of obstetrics and gynaecology, 1987, 94:620-635.
343. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. American journal of epidemiology, 1993, 137:54-63.
344. Armitage P. Clinical trials in the secondary prevention of myocardial infarction and stroke. Thrombosis and haemostasis, 1980, 43:90-98.
345. Posthuma WFM, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? British medical journal, 1994, 308:1268-1269.
346. Cauley JA et al. Prevalence and determinants of estrogen replacement therapy in elderly women. American journal of obstetrics and gynecology, 1990, 163:1438-1444.
347. Pettitti DB et al. Coronary heart disease and estrogen replacement therapy - can compliance bias explain the results of observational studies? Annals of epidemiology, 1994, 4:115-118.
348. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. British medical bulletin, 1992, 48:276-308.
349. Sullivan JM et al. Postmenopausal estrogen use and coronary atherosclerosis. Annals of internal medicine, 1988, 108:358-363.
350. Gruchow HW et al. Postmenopausal use of estrogen and occlusion of coronary arteries. American heart journal, 1988, 115:954-963.
351. McFarland KF et al. Risk factors and non-contraceptive estrogen use in women with and without coronary disease. American heart journal, 1989, 117:1209-1214.
352. Hong MK et al. Effects of estrogen replacement therapy on serum lipid value and angiographically defined coronary artery disease in postmenopausal women. American journal of cardiology, 1992, 69:176-178.
353. Sullivan JM et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Archives of internal medicine, 1990, 150:2557-2562.
354. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. Maturitas, 1996, 23:209-216.
355. Hallberg L, Svanborg A. Cholesterol, phospholipids and triglycerides in plasma in 50-year-old women. Influence of menopause, body-weight, skinfold thickness, weight-gain, and diet in a random population sample. Acta medica Scandinavica, 1967, 181:185-194.
356. Kannel WB et al. Menopause and risk of cardiovascular disease. The Framingham Study. Annals of internal medicine, 1976, 85:447-452.
357. Farish E et al. Effects of bilateral oophorectomy on lipoprotein metabolism. British journal of obstetrics and gynaecology, 1990, 97:78-82.
358. Campos H et al. Differences in low-density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. Journal of clinical endocrinology and metabolism, 1988, 67:30-35.
359. Campos H et al. Differential effects of estrogen on low-density lipoprotein subclasses in healthy menopausal women. Metabolism: clinical and experimental, 1993, 42:1153-1158.
360. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: physiology and pharmacology. Chicago, IL, Year Book Medical Publishers, 1987:187-208.
361. Lobo RA. Clinical review 27. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. Journal of clinical endocrinology and metabolism, 1991, 73:925-930.
362. Tikkanen MJ et al. High-density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. Journal of clinical endocrinology and metabolism, 1982, 54:1113-1117.
363. Tikkanen MJ, Nikkilä EA, Vartiainen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet, 1978, ii:490-491.
364. Walsh BW et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England journal of medicine, 1991, 325:1196-1204.
365. Tikkanen MJ et al. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. Maturitas, 1986, 8:7-17.
366. Krauss RM. Effects of progestational agents on serum lipids and lipoproteins. Journal of reproductive medicine, 1982, 27:503-510.
367. Rijpkema AHM, van den Sanden AA, Ruijs AHC. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas, 1990, 12:259-285.
368. Newnham HH. Oestrogens and atherosclerotic vascular disease - lipid factors. Baillière's clinical endocrinology and metabolism, 1993, 7:61-93.
369. Soma M et al. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women. Lancet, 1991, 337:612.
370. Nabulsi AA et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. New England journal of medicine, 1993, 328:1069-1075.
371. Devor M et al. Estrogen replacement therapy and the risk of venous thrombosis. American journal of medicine, 1992, 92:275-282.
372. Boston Collaborative Drug Surveillance Program. Surgically confirmed gallbladder disease, venous thromboembolism and breast tumours in relation to postmenopausal estrogen therapy. New England journal of medicine, 1974, 290:15-19.
373. Meilahn EN et al. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Annals of epidemiology, 1992, 2:445-455.
374. Sporrong T et al. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. British journal of obstetrics and gynaecology, 1990, 97:939-944.
375. Judd HL et al. Estrogen replacement therapy: indications and complications. Annals of internal medicine, 1983, 98:195-205.
376. Hamsten A. Coagulation factors and hyperlipidaemia. Current opinion in lipidology, 1991, 2:266-271.
377. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. British medical journal, 1992, 305:567-574.
378. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten-year mortality rates in newly diagnosed diabetics, borderline diabetics, and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia, 1982, 22:79-84.
379. Fuller JH et al. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. British medical journal, 1983, 287:867-870.
380. Ronnemaa T et al. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and non-diabetic subjects. Arteriosclerosis and thrombosis, 1991, 11:80-90.
381. Ley CJ et al. Insulin resistance, lipoproteins, body fat and hemostasis in non-obese males with angina and normal or abnormal coronary angiograms. Journal of the American College of Cardiology, 1994, 23:377-383.
382. Elliott TG, Viberti G. Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal; review. Baillière's clinical endocrinology and metabolism, 1993, 7:1079-1103.
383. Cagnacci A et al. Effects of low doses of transdermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. Journal of clinical endocrinology and metabolism, 1992, 74:1396-1400.
384. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol and ethinyl estradiol for six months. American journal of obstetrics and gynecology, 1972, 114:378-392.
385. Godsland IF et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism: clinical and experimental, 1993, 42:846-853.
386. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease. American journal of clinical nutrition, 1956, 4:20-34.
387. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. American journal of clinical nutrition, 1992, 55:950-954.
388. Laragh JH et al. Oral contraceptives: renin, aldosterone and high blood pressure. Journal of the American Medical Association, 1967, 201:918-922.
389. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. Journal of reproductive medicine, 1985, 30:805-810.
390. Barrett-Connor E. Putative complications of estrogen replacement therapy: hypertension, diabetes, thrombophlebitis, and gallstones. In: Korenman SG, ed. The menopause. Biological and clinical consequences of ovarian failure: evaluation and management. (Proceedings of the Symposium on the Menopause, 5-8 March 1989, Napa, CA.) Norwell, MA, Serona Symposia USA, 1990:199-209.
391. Lind T et al. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. British journal of obstetrics and gynaecology, 1979, 86(Suppl. 3):1-29.
392. Luotola H. Blood pressure and hemodynamics in postmenopausal women during estradiol-17β substitution. Annals of clinical research, 1983, 15(Suppl. 38):1-121.
393. Magness RR, Rosenfeld CR. Local and systemic estradiol-17 beta: effects on uterine and systemic vasodilation. American journal of physiology, 1989, 256(4, Part 1):E536-E542.
394. Volterrani M, Rosano GMC, Collins P. Effect of estradiol-17β upon forearm blood flow in menopausal women: a double-blind randomized study. Circulation, 1993, 88(4, Suppl. 2):I-376 (Abstract).
395. Ginsburg J, Hardiman P. Cardiovascular effects of transdermal oestradiol in postmenopausal women. Annals of the New York Academy of Sciences, 1990, 592:424-425.
396. Gangar KF et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet, 1991, 338:839-842.
397. Pines A et al. The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. American journal of obstetrics and gynecology, 1991, 164:806-812.
398. Penotti M et al. Blood flow variations in internal carotid and middle cerebral arteries induced by post-menopausal hormone replacement therapy. American journal of obstetrics and gynecology, 1993, 169:1226-1232.
399. Collins P et al. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation, 1994, 90:1964-1968.
400. Williams JK et al. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. Journal of the American College of Cardiology, 1992, 20:452-457.
401. Reis SE et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation, 1994, 89:52-60.
402. Rosano GM et al. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet, 1993, 342:133-136.
403. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. International journal of cancer, 1993, 54:594-606.
404. Miller AB, Bulbrook RD. UICC Multidisciplinary Project on Breast Cancer. The epidemiology, aetiology and prevention of breast cancer. International journal of cancer, 1986, 37:173-177.
405. Committee on the Relationship between Oral Contraceptives and Breast Cancer, Institute of Medicine, Division of Health Promotion and Disease Prevention. Oral contraceptives and breast cancer. Washington, DC, National Academy Press, 1991.
406. Committee on Safety of Medicines. Carcinogenicity tests of oral contraceptives. London, Her Majesty's Stationery Office, 1972.
407. Dickson RB, Lippman ME. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocrine reviews, 1987, 8:29-43.
408. Dickson RB, Thompson EW, Lippman ME. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. Journal of steroid biochemistry, 1990, 37:305-316.
409. King RJB. Biology of female sex hormone action in relation to contraceptive agents and neoplasia. Contraception, 1991, 43:527-542.
410. World Health Organization. Cancer incidence in five continents, Volume VI. Lyon, International Agency for Research on Cancer, 1992.
411. Barrett-Connor E. Postmenopausal estrogen and the risk of breast cancer. Annals of epidemiology, 1994, 4:177-180.
412. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer, 1956, 9:927.
413. Kelsey JL, Gammon MD. The epidemiology of breast cancer. CA: a cancer journal for clinicians, 1991, 41:146-165.
414. Irwin KL et al. Hysterectomy, tubal sterilization, and the risk of breast cancer. American journal of epidemiology, 1988, 127:1192-1201.
415. Henderson BE et al. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985, 56:1206-1208.
416. MacMahon B et al. Age at menarche, probability of ovulation and breast cancer risk. International journal of cancer, 1982, 29:13-16.
417. White E. Projected changes in breast cancer incidence due to the trend toward delayed childbearing. American journal of public health, 1987, 77:495-497.
418. Colditz GA et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. Journal of the American Medical Association, 1990, 264:2648-2653.
419. Pike MC, Bernstein L, Spicer DV. The relationship of exogenous hormones to breast cancer risk. In: Niederhuber JE, ed. Current therapy in oncology. St Louis, MO, BC Decker, 1993:292-303.
420. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast cancer research and treatment, 1982, 2:5-73.
421. Secreto G et al. Androgens and breast cancer in premenopausal women. Cancer research, 1989, 49:471-476.
422. Secreto G et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer research, 1991, 51:2572-2576.
423. Adlercreutz H et al. Diet and plasma androgens in post-menopausal vegetarian and omnivorous women and post-menopausal women with breast cancer. American journal of clinical nutrition, 1989, 49:433-442.
424. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. European journal of cancer and clinical oncology, 1989, 25:1953-1959.
425. Grady D, Ernster V. Does postmenopausal hormone therapy cause breast cancer? American journal of epidemiology, 1991, 134:1396-1400.
426. Mack TM. Hormone replacement therapy and cancer. Baillière's clinical endocrinology and metabolism, 1993, 7:113-149.
427. Pike MC. Age-related factors in cancers of the breast, ovary and endometrium. Journal of chronic diseases, 1985, 49(Suppl.):59-69.
428. Steinberg KK et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. Journal of the American Medical Association, 1991, 265:1985-1990.
429. Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: an expanded case-control study. British journal of cancer, 1986, 54:825-832.
430. McDonald JA et al. Menopausal estrogen use and the risk of breast cancer. Breast cancer research and treatment, 1986, 7:193-199.
431. Nomura AMY et al. The association of replacement estrogens with breast cancer. International journal of cancer, 1986, 37:49-53.
432. Wingo PA et al. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. Journal of the American Medical Association, 1987, 257:209-215.
433. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. International journal of cancer, 1988, 42:832-838.
434. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Medical journal of Australia, 1988, 148:217-221.
435. Bergkvist L et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. New England journal of medicine, 1989, 321:293-297.
436. Mills PK et al. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer, 1989, 64:591-597.
437. Kaufman DW et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. American journal of epidemiology, 1991, 134:1375-1385.
438. Palmer JR et al. Breast cancer risk after estrogen replacement therapy: results from the Toronto breast cancer study. American journal of epidemiology, 1991, 134:1386-1395.
439. Yang CP et al. Non-contraceptive hormone use and risk of breast cancer. Cancer causes and control, 1992, 3:475-479.
440. Colditz GA et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer causes and control, 1992, 3:433-439.
441. La Vecchia C et al. Non-contraceptive estrogen and breast cancer: an update. International journal of cancer, 1992, 50:161-162.
442. Hulka BS. Steroid hormone replacement and risk of breast cancer. Cancer, 1994, 74(Suppl. 3):1111-1124.
443. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiologic reviews, 1993, 15:98-107.
444. Krieger N et al. Risk factors for adenomatous endometrial hyperplasia: a case-control study. American journal of epidemiology, 1986, 123:291-301.
445. Kurman RJ, Kaminski PF, Norris HJ. The behaviour of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer, 1985, 56:403-412.
446. Pitot C. Fundamentals of oncology. New York, Dekker, 1986.
447. Voigt LF, Weiss NS. Epidemiology of endometrial cancer. In: Surwit E, Alberts D, eds. Endometrial cancer. Boston, MA, Kluwer Academic Publishers, 1989:1-21.
448. Nyholm HC et al. Plasma oestrogens in postmenopausal women with endometrial cancer. British journal of obstetrics and gynaecology, 1993, 100:1115-1119.
449. Austin H et al. Endometrial cancer, obesity, and body fat distribution. Cancer research, 1991, 51:568-572.
450. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens: characteristics of use in relation to the risk of endometrial carcinoma. Annals of epidemiology, 1993, 3:308-318.
451. Voigt LF et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet, 1991, 338:274-277.
452. Schwartzbaum JA et al. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. American journal of epidemiology, 1987, 126:851-860.
453. Collins I et al. Estrogen use and survival in endometrial cancer. Lancet, 1980, ii:961-964.
454. Chu J et al. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. American journal of obstetrics and gynecology, 1982, 143:569-573.
455. Whitehead MI et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New England journal of medicine, 1981, 305:1599-1605.
456. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstetrics and gynecology, 1993, 81:265-271.
457. Gambrell RD et al. Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. Journal of the American Geriatrics Society, 1979, 27:389-394.
458. Persson I et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. British medical journal, 1989, 298:147-151.
459. Thom MH et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet, 1979, ii:455-457.
460. Jick SS, Walker AM, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology, 1993, 4:20-24.
461. Annegers JF et al. Ovarian cancer: incidence and case-control study. Cancer, 1979, 43:723-729.
462. Franceschi S et al. Risk factors for epithelial ovarian cancer in Italy. American journal of epidemiology, 1982, 115:714-719.
463. Tzonou A et al. The epidemiology of ovarian cancer in Greece: a case-control study. European journal of cancer and clinical oncology, 1984, 20:1045-1052.
464. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. British journal of cancer, 1989, 60:592-598.
465. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American journal of epidemiology, 1992, 136:1184-1203.
466. Kim JW et al. Estrogen and progesterone receptor assay in carcinoma of the cervix with monoclonal antibodies. Gynecologic oncology, 1992, 47:306-310.
467. Masood S et al. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. Cancer, 1993, 72:511-518.
468. Crook T et al. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85:8820-8824.
469. Chan W, Klock G, Bernard H. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasms. Journal of virology, 1989, 63:3261-3269.
470. Mittal R et al. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstetrics and gynecology, 1993, 81:5-12.
471. Adami HO et al. Risk of cancer in women receiving hormone replacement therapy. International journal of cancer, 1989, 44:833-839.
472. Hunt K et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. British journal of obstetrics and gynaecology, 1987, 94:620-635.
473. Hulka BS. Hormonal contraceptives and risk of cervical cancer. In: Michal F, ed. Safety requirements for contraceptive steroids. (Proceedings of a Symposium on Improving Safety Requirements for Contraceptive Steroids, Geneva, 2-5 February 1987.) Cambridge, Cambridge University Press, 1989:84-96.
474. Garau JM et al. Estrogen and progesterone receptor assays on the vulvar epithelium. Journal of reproductive medicine, 1986, 31:987-991.
475. Mosny DS, Brito F, Bender HG. Immunohistochemical investigations of estrogen receptors in normal and neoplastic squamous epithelium of the vulva. Journal of reproductive medicine, 1990, 35:1005-1007.
476. MacLean AB, Nicol LA, Hodgins MB. Immunohistochemical localization of estrogen receptors in the vulva and vagina. Journal of reproductive medicine, 1990, 35:1015-1016.
477. Newcomb PA, Weiss NS, Daling JR. Incidence of vulvar carcinoma in relation to menstrual, reproductive, and medical factors. Journal of the National Cancer Institute, 1984, 73:391-396.
478. Brinton LA et al. Case-control study of cancer of the vulva. Obstetrics and gynecology, 1990, 75:859-866.
479. Sherman KJ et al. Hormonal factors in vulvar cancer. A case-control study. Journal of reproductive medicine, 1994, 39:857-861.
480. te Velde ER, van Leusden HA. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet, 1994, 343:654-658.
481. American College of Physicians. Guidelines for counselling postmenopausal women about preventive hormone therapy. Annals of internal medicine, 1992, 117:1038-1041.
482. Daly E et al. Hormone replacement therapy in a risk-benefit perspective. In: Berg G, Hammar M, eds. The modern management of the menopause: a perspective for the 21st century. New York, NY, Parthenon Publishing Group, 1993:473-497.
483. Barlow DH. Hormone replacement therapy and other menopause-associated conditions. British medical bulletin, 1991, 48:356-367.
484. Coope J, Marsh J. Can we improve compliance with long-term HRT? Maturitas, 1992, 15:151-158.
485. Ravnikar VA. Compliance with hormone therapy. American journal of obstetrics and gynecology, 1987, 156:1332-1334.
486. Hahn RG. Compliance considerations with oestrogen replacement: withdrawal bleeding and other factors. American journal of obstetrics and gynecology, 1989, 161:1854-1858.
487. Ryan PJ et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. British journal of obstetrics and gynaecology, 1992, 99:325-328.
488. Hunter MS. The effects of estrogen therapy on mood and well-being. In: Berg G, Hammar M, eds. The modern management of the menopause: a perspective for the 21st century. (Proceedings of the VII International Conference on the Menopause, Stockholm, June 1993.) Carnforth, Parthenon Publishing Group, 1994:177-184.
489. Holzer G. Ovarian failure and joints. In: Berg G, Hammar M, eds. The modern management of the menopause: a perspective for the 21st century. (Proceedings of the VII International Conference on the Menopause, Stockholm, June 1993.) Carnforth, Parthenon Publishing Group, 1994:359-367.
490. Hall G, Spector T. The use of estrogen replacement as an adjunct therapy in rheumatoid arthritis. In: Berg G, Hammar M, eds. The modern management of the menopause: a perspective for the 21st century. (Proceedings of the VII International Conference on the Menopause, Stockholm, June 1993.) Carnforth, Parthenon Publishing Group, 1994:369-375.
491. Brenner DE et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. American journal of epidemiology, 1994, 140:262-267.
492. Paganini-Hill A et al. Estrogen deficiency and Alzheimer's disease in women. American journal of epidemiology, 1994, 140:256-261.
493. Kampen DL. Estrogen use and verbal memory in healthy postmenopausal women. Obstetrics and gynecology, 1994, 83:979-983.
494. Lauritzen C. Das kolorektale Karzinom und Hormonbehandlung in der Menopause. [Colorectal carcinoma and substitution hormone treatment in menopause.] Zentralblatt für Gynäkologie, 1990, 112:1493-1494.
495. La Vecchia C, Franceschi S. Reproductive factors and colorectal cancer. Cancer causes and control, 1991, 2:193-200.
496. Weiss NS et al. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. Journal of the National Cancer Institute, 1981, 67:57-60.
497. Wu AH et al. Alcohol, physical activity and other risk factors for colorectal cancer. A prospective study. British journal of cancer, 1987, 55:687-694.